WellDoc Expands Strategic Advisory Team

WellDoc Expands Strategic Advisory Team

February 28, 2018

Jill Berger, Kristine Seymour and Jason Rose to Serve as WellDoc Advisors

Columbia, Maryland, February 28, 2018 – WellDoc®, a leading digital therapeutic company, announced today that it has expanded its advisory team with experts in employer benefits, payer relations and healthcare information technology (IT). Jill Berger, Kristine Seymour and Jason Rose now serve as
strategic advisors to the company.

“Jill, Kristine and Jason are important additions to the WellDoc strategic advisory team,” said WellDoc President and CEO Kevin McRaith. “As we continue to dive deeper into the employer and health plan arena, these new advisors bring the right blend of expertise and experience to the table.”

Ms. Berger is currently an independent consultant at Berger & Moore Advisors, working with employers and health plan partners to evaluate health improvement programs. She has more than 25 years of experience in managing employer benefits and developing innovative solutions for employers and health plans to transform healthcare. Formally the Vice President of Health & Welfare for Marriott International, Ms. Berger was responsible for the strategy, design and management of Marriott’s health and well-being programs—honing in on the need for quality improvement and greater engagement with
employees about their health.

Ms. Seymour is currently the CEO of Kristine Seymour Consulting, LLC, where she works with a variety of clients on healthcare and insurance issues. She is focused on supporting payers and providers as they transition to value-based reimbursement, while identifying emerging technologies to assist members with their healthcare needs. Previously, Ms. Seymour worked as a senior commercial leader at Humana where she oversaw the commercial strategy for the employer group, wellness and specialty benefit offerings in Illinois, Michigan, Minnesota and Wisconsin. Before her time at Humana, Kristine served as Executive Vice President of the Employee Benefit Group at Milwaukee insurance consultant, Willis (formerly HRH and Frank F. Haack & Associates) and Blue Cross Blue Shield of Wisconsin.

Mr. Rose is a healthcare IT expert and entrepreneur with nearly 25 years of experience focused on launching disruptive products that drive digital health innovation and value-based care. His career includes leading data-driven product development, corporate strategy, business development, strategic partnerships, technology implementation and solution portfolio commercialization. Over the past decade, Mr. Rose served as a senior executive at Inovalon, supporting the Company from start-up through initial public offering. He led the development for several products at Inovalon, as well as the
expansion of the company’s technology presence across the healthcare marketplace.

WellDoc’s other strategic advisors include:

  • Frank Baitman
  • John L. Brooks III
  • Scott Cousino
  • Krista Drobac
  • Kristine Mullen
  • Theresa Neil
  • Daniel Rosenberg
  • Michael Stocker, MD
  • H. Thomas Watkins

About WellDoc®

WellDoc® is a leading digital health company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes. Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. For more information, visit www.welldoc.com.